Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TALPHERA, INC. Director's Dealing 2018

Jan 26, 2018

35181_dirs_2018-01-26_26f4816e-c483-4301-a727-0c4557cacb2b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACELRX PHARMACEUTICALS INC (ACRX)
CIK: 0001427925
Period of Report: 2018-01-22

Reporting Person: Hamel Lawrence G (Chief Development Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-01-22 Stock Option (Right to Buy) $2 A 95000 Acquired 2028-01-21 Common Stock (95000) Direct

Footnotes

F1: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months.

F2: Issued pursuant to the 2011 Equity Incentive Plan.